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Abstract
Background: Newborn screening (NBS) for cystic fibrosis (CF) improves nutritional outcomes. Despite early dietetic
intervention some children fail to grow optimally. We report growth from birth to 2 years in a cohort of children
diagnosed with CF by NBS and identify the variables that influence future growth.
Methods: One hundred forty-four children were diagnosed with CF by the West Midlands Regional NBS laboratory
between November 2007 and October 2014. All anthropometric measurements and microbiology results from the
first 2 years were collated as was demographic and CF screening data. Classification modelling was used to identify
the key variables in determining future growth.
Results: Complete data were available on 129 children. 113 (88%) were pancreatic insufficient (PI) and 16 (12%)
pancreatic sufficient (PS). Mean birth weight (z score) was 3.17 kg (− 0.32). There was no significant difference in
birth weight (z score) between PI and PS babies: 3.15 kg (− 0.36) vs 3.28 kg (− 0.05); p = 0.33. By the first clinic visit
the difference was significant: 3.42 kg (− 1.39) vs 4.60 kg (− 0.48); p < 0.0001. Weight and height remained lower in PI
infants in the first year of life. In the first 2 years of life, 18 (14%) infants failed to regain their birth weight z score.
The median time to achieve a weight z score of − 2, − 1 and 0 was 18, 33 and 65 weeks respectively. The median
times to reach the same z scores for height were 30, 51 and 90 weeks. Birth weight z score, change in weight z
score from birth to first clinic, faecal elastase, isolation of Pseudomonas aeruginosa, isolation of Staphylococcus
aureus and sweat chloride were the variables identified by the classification models to predict weight and height in
the first and second year of life.
Conclusions: Babies with CF have a lower birth weight than the healthy population. For those diagnosed with CF
by NBS, the weight difference between PI and PS babies was not significantly different at birth but became so by
the first clinic visit. The presence of certain factors, most already identifiable at the first clinic visit can be used to
identify infant at increased risk of poor growth.
Background
The implementation of newborn screening (NBS) has
fundamentally changed the care of children with cystic
fibrosis (CF) [1]. They are now identified in the first few
weeks of life and no longer have to wait for the present-
ing symptoms to become severe enough to warrant in-
vestigation [2]. Historically, this wait was often
associated with failure to thrive and irreversible lung
damage [3]. CF-NBS improves outcomes, particularly
nutritional ones [4, 5]. This is important for children
with CF as nutritional status is closely related to lung
function, quality of life and ultimately survival [6]. The
nutritional benefits of CF-NBS are maintained into
adulthood [7].
Despite early diagnosis and the initiation of appropri-
ate treatment, some infants diagnosed with CF by NBS
do not achieve optimal growth [8]. Antenatal factors
such as maternal smoking or poor nutrition can contrib-
ute to this, as can postnatal factors such as acute or
chronic respiratory infections, adherence with therapy,
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nutritional intake, dose of pancreatic enzyme replace-
ment therapy and other environmental exposures [9,
10]. It would be useful for clinicians to know which vari-
ables have the most significant impact on infant growth.
This would mean children at higher risk of growth fail-
ure could be identified and considered for more careful
monitoring of growth and/or earlier nutritional support.
We collated NBS, demographic, microbiology and
growth data on a cohort of children diagnosed with CF
by NBS. We then used classification modelling to estab-
lish the factors / variables useful in predicting infant
growth.
Method
Study population
A cohort of 144 children diagnosed with CF by NBS was
identified. This included all babies with a positive CF
NBS from the West Midlands Regional Screening La-
boratory between 1st November 2007 and 31st October
2014 who had a confirmed diagnosis of CF (identifica-
tion of two CF-causing mutations and/or a sweat chlor-
ide ≥60mmol/L). Five children categorized as Cystic
Fibrosis Screen Positive Inconclusive Diagnosis (CF
SPID) [11] were excluded. Two children had died and
two moved out of area. A further six patients were ex-
cluded due to incomplete datasets. The remaining 129
children attended one of the two tertiary CF centres in
the region: Birmingham Children’s Hospital and Royal
Stoke University Hospital. Although these two centres
work independently, both follow the UK CF Trust and
European CF Society Standards of care resulting in simi-
lar clinical practices [12, 13].
Data collection
Demographic and newborn screening data were col-
lected. These included date of diagnosis (taken as date of
first clinic visit or date of diagnosis of meconium ileus),
gender, ethnicity, birth weight, the presence of meco-
nium ileus, mean immunoreactive trypsinogen, CFTR
mutations, sweat chloride, faecal elastase (measured at
first clinic appointment), weight at first clinic visit and
mode of feeding (exclusive breast / exclusive formula /
mixed). All weight and length measurements recorded
in the first 2 years of life were then collated. Insufficient
data points were available for head circumference to
allow meaningful analysis. We also recorded age at first
isolation of Pseudomonas aeruginosa and Staphylococcus
aureus. These data were obtained from the West Mid-
lands NBS Laboratory database, patient’s clinical notes
and the electronic results systems at the two CF Centres.
All height and weight measurements were converted
into z scores using the WHO-UK anthropometric calcu-
lator. This corrects for sex and gestational age. To sum-
marise growth, the following four outcomes were
calculated for each child: mean weight z score in first
year of life, mean weight z score in second year of life,
mean height z score in the first year of life and mean
height z score in second year of life. The median time
for children to achieve height and weight z scores of − 2,
− 1 and 0 was calculated and children who did not re-
gain their birth weight z score in the first 2 years of life
were identified.
Classification modelling to identifying variables affecting
growth from 0 to 2 years
Before classification modelling could be undertaken, the
cohort had to be validated using a clustering algorithm
(k-means) [14]. This ensured it was representative of the
UK CF population. The anthropometric measurements
as well as the demographic, newborn screening and
microbiology data were included as inputs and the
mathematically generated clusters were scrutinised by
the CF clinicians (MD, WC and FG) to ensure they cor-
responded to clinical phenotypes. Decision-tree classifi-
cation models were then generated to determine the
variables that predicted future growth. Inputs were the
demographic, newborn screening and infection variables.
The model analyses all the inputs but only uses those
with predictive effect in the decision trees. The four out-
comes were the mean z scores for height and weight in
the first and second year of life. These outputs were
chosen as the z scores frequently varied significantly
over time meaning a z score from a single time point
would not have been representative. Each classification
model was validated using a stratified five-fold cross-
validation method. This approach is used when the sam-
ple size does not allow for a representative split (such as
70% / 30%) for model training and validation sets. The
data is split into five sets ensuring each set has propor-
tional representation of all classes in each set. Modelling
is repeated five times each using a different fifth of the
data for validation. The final model reported is the one
obtained using all the data, however, the error reported
is the mean error out of the five repeats.
Results
Patient demographics
The sample included 63 (49%) girls and 66 (51%) boys.
Mean (SD) gestation age was 38.9 (1.8) weeks with 8
(6%) born < 37 weeks gestation. Twenty one (16%) chil-
dren had meconium ileus. Median (IQR) age at diagnosis
was 22 (17–25) days. This was later in pancreatic suffi-
cient (PS) compared to pancreatic insufficient (PI) ba-
bies: 25.5 (21.5–32) vs 20 (16–25), p = 0.004. 121/129
(94%) children were Caucasian and 8/129 (6%) were
Asian, Afro-Caribbean or other white. 68/129 (53%)
were homozygous and 122/129 (95%) heterozygous for
the Phe508del variant.
Patterson et al. BMC Pediatrics          (2019) 19:356 Page 2 of 7
Nutrition and effect of pancreatic function
The mean (SD) birth weight of the entire cohort was
3.17 (0.51) kg giving a mean (SD) z score of − 0.32
(1.13). The mean (SD) birth weight was 3.21 (0.50) kg
for boys and 3.12 (0.53) kg for girls. The mean (SD)
birth weight z scores were − 0.35 (1.07) for boys and −
0.30 (1.20) for girls. Using a faecal elastase cut-off of
200 μg/g, 113 (88%) children were PI and 16 (12%) PS.
When reviewed at their first clinic visit, 29 (22%) infants
were exclusively breast-fed, 60 (47%) were exclusively
formula milk and 40 (31%) were mixed feeding. There
was no difference in mode of feeding between PI and PS.
All babies were started on standard treatment on the
day of diagnosis. The difference in weight between PI
and PS infants was not significant at birth but became
so by the time of the first clinic visit. Height and weight
was significantly lower in PI children in the first year of
life. The difference was less in the second year and no
longer significant. See Table 1. In the first 2 years of life,
18 (14%) of infants failed to regain their BW z score, all
of these were pancreatic insufficient. The median time
for children to achieve a weight z score of − 2, − 1 and 0
was 18, 33 and 65 weeks respectively. The median times
to reach the same z scores for height were 30, 51 and
90 weeks.
Microbiology data
All the children were on oral Staphylococcus aureus
prophylaxis. Staphylococcus aureus was isolated in 16 of
the 129 children in the first 2 years of life. The median
(IQR) age of the first isolate was 0.22 (0.08–0.63) years.
Pseudomonas aeruginosa was isolated in 45 children in
the first 2 years of life. The median (IQR) age of the first
isolate was 1.18 (0.82–1.49) years. All these isolates were
non-mucoid. No child met the Leeds Criteria for chronic
Pseudomonas aeruginosa infection in the first 2 years of
life [15].
Variables affecting future growth
The unsupervised cluster analysis identified two distinct
groups. See Table 2 in Appendix. The CF clinicians
agreed the clusters were clinically relevant as they repre-
sented PI and PS phenotypes. This validated the cohort.
Decision tree classification modelling was therefore
undertaken to identify the variables that could be used
to predict the growth outcomes listed above. See Fig. 1.
Across the four models, birth weight z score, change in
weight z score from birth to first clinic, faecal elastase,
isolation of Pseudomonas aeruginosa, isolation of
Staphylococcus aureus and sweat chloride were the vari-
ables of use in predicting future growth. Importantly,
the mode of feeding was not identified as a predictor of
infant growth by any of the classification models.
Discussion
This study reports growth from birth to 2 years in a co-
hort of children diagnosed with CF by NBS. Classifica-
tion modelling is also used to identify the variables
Table 1 Weight at birth and first clinic visit for pancreatic sufficient and insufficient infants
Pancreatic insufficient (n = 113) Pancreatic sufficient (n = 16) p value
Birth weight
kg 3.15 (0.51) 3.28 (0.53) 0.33
z score −0.36 (1.11) −0.05 (1.26) 0.29
First clinic weight
kg 3.42 (0.80) 4.60 (1.49) < 0.0001
z score −1.39 (1.27) −0.48 (1.62) 0.005
Change in weight z score from birth to first clinic
Absolute −1.03 (0.81) −0.43 (1.06) 0.023
Rate −0.35 (0.28) −0.10 (0.35) 0.0007
Weight in year 1
z score −0.73 (1.27) − 0.25 (1.16) < 0.0001
Weight in year 2
z score −0.16 (0.93) 0.37 (1.02) 0.191
Height in year 1
z score −0.67 (1.29) −0.12 (1.18) 0.001
Height in year 2
z score −0.37 (1.03) −0.19 (1.00) 0.255
All data is presented as mean (SD). Rate: change per week
kg kilograms
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affecting infant growth, to our knowledge this it is the
first time this methodology has been used in this group.
Previous cohort studies show CF babies have a lower
birth weight than healthy children although it is usually
still within the normal range [16, 17]. Our cohort follows
this pattern with a mean birth weight z scores of − 0.32.
The lower birth weight may relate to gestational age as
this was on average 38.9 weeks. Although the WHO-UK
anthropometric calculator corrects the birth weight z
scores for gestational age, it only does this for those <
37 weeks. CFTR may have a role in prenatal growth. As
children with PS CF have higher residual CFTR function
than PI CF infants, this would be consistent with the ob-
servation of lower birth weights in PI infants. This hy-
pothesis requires replication in a larger cohort as the
difference in birth weight between PI and PS infants was
Fig. 1 Decision tree models generated by classification modelling showing the factors predictive of mean weight and height z scores in the first
and second year of life
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not statistically significant. Interestingly the gestation
age was very similar for PI and PS infants (38.5 versus
38.8 weeks). Infants with CF have been shown to have
reduced levels of insulin like growth factor [18]. This
may explain the difference in birth weight between CF
and non-CF babies and why some children with well
managed CF still fail to reach their growth potential.
Postnatally, pancreatic function has a clear effect with
the weight difference between the PS and PI infants be-
coming statistically significant at the first clinic visit when
the child had ‘untreated CF’ for an average of 22 days. The
degree of faltering growth observed in this short period
was one of the most important variables identified by the
classification model in predicting infant growth. There-
fore, infants who experience the most severe nutritional
consequences before treatment, continue to do so after
this is started. These infants are likely to be those with
mutations associated with the most severe loss of CFTR
function. Despite treatment with pancreatic enzyme re-
placement therapy, PI infants had a significantly lower
height and weight in the first year of life than PS infants.
This difference reduced in the second year showing catch-
up growth can be achieved with prolonged treatment pan-
creatic enzyme replacement therapy and appropriate nu-
tritional support.
Infants with CF who are PI are more likely to have
lower weight and height z scores than those who are PS
[16]. It is therefore unsurprising that faecal elastase is
one of the variables used by the classification models to
predict future growth. PI infants usually have at least
one class I, II or III mutation which are associated with
higher sweat chloride which explains its inclusion in
some of the models. Chronic infection with PA has an
adverse effect on nutritional parameters in children with
CF [17]. In our study, a single isolation of PA was linked
with reduced infant weight and height. It is possible this
was a direct effect of the PA infection or more likely that
children who isolate PA have more significant lung dis-
ease which affects growth. The effects of acute and
chronic SA infection on the growth of children in CF is
not well known but early infection, especially occurring
as a co-infection with other organisms, may be associ-
ated with severe lung disease which would affect growth
[19, 20].
The importance of birth weight in predicting future
growth is well established in the healthy children. The
GECKO Drenthe Birth Cohort included 2447 healthy in-
fants and identified birth weight and mode of feeding as
the most important factors at predicting growth in the
first 6 months of life [18]. The classification modelling
in our study did not identify mode of feeding as a factor
predictive of future growth although the sample size
may have been too small to identify this. Early nutri-
tional status is a key predictor of future health in chil-
dren with CF [20]. It is therefore unsurprising that CF
children with low birth weight have increased pulmonary
disease in later childhood [17]. Increasing the birth
weight of children with CF would therefore have long
term health benefits. This could only be achieved
through general public health measures targeting all
pregnant mothers as it is unusual for the diagnosis of CF
to be made prenatally.
Our study has several limitations. As we did not have
a matched control group of non-CF infants from the
same area we relied on the WHO-UK anthropometric
calculator to generate z scores but accept this may miss
local variations. There are potentially a huge number of
variables that could affect infant growth. Due to the
retrospective nature of this study we were limited as to
which factors we could collect data on. Relevant
Appendix
Table 2 Centroid values from the unsupervised cluster analysis used to validate the dataset
Variable Cluster 1 (members: 113) Cluster 2 (members: 16)
Birth weight z score −0.42 −0.72
Change in weight z score from birth to first clinic visit 0.00 0.01
Faecal Elastase 15 466
Sweat chloride 99 46.5
Immunoreactive trypsinogen 172 85.5
CFTR Mutation 1 Phe508del Phe508del
CFTR Mutation 2 Phe508del Arg117His
Gestation 39 39.5
Mean length z score in year 1 −0.68 −0.14
Mean length z score in year 2 −0.24 − 0.12
Mean weight z score in year 1 −0.67 − 0.04
Mean weight z score in year 2 0.18 0.19
All data presented as mean apart from genotype which indicates the most prevalent mutation
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variables which we were unable to collect data on in-
cluded: parental height and weight, maternal smoking
status, maternal diet during pregnancy, pulmonary exac-
erbations, treatment regimen, nutritional support, adher-
ence with treatment and socioeconomic status. All of
these may affect infant growth [9]. We used mean z
scores over the first and second years of life for height
and weight as our outcome for the statistical modelling.
We accept this approach lacks granularity but the wide
variation seen in the individual measurements it gave us
the most useful summary outcome. We considered using
alternative growth indices calculated from the weight
and height measurements. However, the WHO does not
recommend using BMI for age in children under 2 years
and as percentage weight-for-height is not independent
of the raw data it would have made the modelling results
difficult to interpret.
Conclusion
This cohort study confirms children with CF have a
lower birth weight than non-CF babies. The effect of
pancreatic insufficiency on weight was not significant at
birth but became so by the first clinic visit and remained
so for the first year of life. A number of CF babies did
not regain their birth weight z score by 2 years of age.
Identification of predictors of poor infant growth such
as low birth weight and poor weight gain from birth to
first clinic should enable focused interventions by clini-
cians and dieticians to optimise nutritional outcomes.
The possible effect of CFTR on antenatal growth and
the role of other factors such as adherence to treatment
and socioeconomic status on infant growth warrants fur-
ther investigation.
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